CardioNexa is a Newton, Massachusetts healthcare technology company building AI-powered clinical optimization infrastructure for cardiovascular disease prevention. It targets the secondary-prevention gap: patients who have already had a heart attack, stroke, or stent but never reach their LDL-C goal. Its clinical engine reviews an entire ASCVD population against current ACC/AHA guidance and produces a prioritized care-team workqueue with a recommended next step, follow-up interval, and pre-drafted documentation for each patient. The company was co-founded by a cardiac surgeon and a technologist and says it plans to expand beyond lipids into hypertension, heart failure, and anticoagulation.